Silva JT, San-Juan R, Fernández-Ruiz M, Aguado JM. Fluoroquinolones for the treatment of latent Mycobacterium tuberculosis infection in liver transplantation. World J Gastroenterol 2019; 25(26): 3291-3298 [PMID: 31341356 DOI: 10.3748/wjg.v25.i26.3291]
Corresponding Author of This Article
Jose Tiago Silva, MD, PhD, Attending Doctor, Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación Hospital “12 de Octubre” (imas12), School of Medicine, Universidad Complutense, 2ª planta, bloque D. Avda. de Córdoba, s/n, Madrid 28041, Spain. email@example.com
Checklist of Responsibilities for the Scientific Editor of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Fluoroquinolones for the treatment of latent Mycobacterium tuberculosis infection in liver transplantation
Jose Tiago Silva, Rafael San-Juan, Mario Fernández-Ruiz, José María Aguado
Jose Tiago Silva, Rafael San-Juan, Mario Fernández-Ruiz, José María Aguado, Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación Hospital “12 de Octubre” (imas12), School of Medicine, Universidad Complutense, Madrid 28041, Spain
Author contributions: Silva JT was responsible for the literature review and the drafting and writing of the manuscript; San-Juan R, Fernández-Ruiz M and Aguado JM contributed to the editing, critical revision and approval of the final version.
Supported by“Plan Nacional de I+D+I”; Instituto de Salud Carlos III (Fondo de Investigaciones Sanitarias [FIS] PI14/00174), Subdirección General de Redes y Centros de Investigació n Cooperativa, Spanish Ministry of Science, Innovation and Universities, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016); and was cofinanced by the European Development Regional Fund (EDRF) "A way to achieve Europe".
Conflict-of-interest statement: The authors have no conflicts of interest related to this publication.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jose Tiago Silva, MD, PhD, Attending Doctor, Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación Hospital “12 de Octubre” (imas12), School of Medicine, Universidad Complutense, 2ª planta, bloque D. Avda. de Córdoba, s/n, Madrid 28041, Spain. firstname.lastname@example.org
Telephone: +34-91-3908000 Fax: +34-91-4695775
Received: February 20, 2019 Peer-review started: February 20, 2019 First decision: April 30, 2019 Revised: May 30, 2019 Accepted: June 7, 2019 Article in press: June 7, 2019 Published online: July 14, 2019
Solid organ transplantation (SOT) is the best treatment option for end-stage organ disease. Newer immunosuppressive agents have reduced the incidence of graft rejection but have increased the risk of infection, particularly due to the reactivation of latent infections due to opportunistic agents such as Mycobacterium tuberculosis. Active tuberculosis (TB) after SOT is a significant cause of morbidity and mortality. Most cases of posttransplant TB are secondary to reactivation of latent tuberculosis infection (LTBI) due to the effects of long-term immunosuppressive therapy. Risk minimization strategies have been developed to diagnose LTBI and initiate treatment prior to transplantation. Isoniazid with vitamin B6 supplementation is the treatment of choice. However, liver transplantation (LT) candidates and recipients have an increased risk of isoniazid-induced liver toxicity, leading to lower treatment completion rates than in other SOT populations. Fluoroquinolones (FQs) exhibit good in vitro antimycobacterial activity and a lower risk of drug-induced liver injury than isoniazid. In the present review, we highlight the disease burden posed by posttransplant TB and summarize the emerging clinical evidence supporting the use of FQs for the treatment of LTBI in LT recipients and candidates.
Core tip: Active tuberculosis after solid organ transplantation, particularly after liver transplantation, has a dismal outcome. This review focuses on the burden of active tuberculosis after liver transplantation and summarizes the most recent data concerning the use of isoniazid for the treatment of latent tuberculosis infection in liver transplant recipients and candidates. In addition, we review the most relevant clinical experience in the use of fluoroquinolones as an alternative approach with a favorable safety profile for the treatment of latent tuberculosis infection in the liver transplant setting.
Citation: Silva JT, San-Juan R, Fernández-Ruiz M, Aguado JM. Fluoroquinolones for the treatment of latent Mycobacterium tuberculosis infection in liver transplantation. World J Gastroenterol 2019; 25(26): 3291-3298
Solid organ transplantation (SOT) is the best treatment option for end-stage organ disease. New immunosuppressive agents have reduced the incidence of acute graft rejection but have increased the risk of infection and the development of de novo malignancies in the long term[1-4]. Prophylactic and preemptive treatment strategies have been especially effective in diminishing the incidence of donor and recipient-derived infections as well as the frequency of most opportunistic infections (OI) in the first six months after transplantation. However, the incidence of active tuberculosis (TB), one of the most concerning OIs after SOT, is still significant. A study that prospectively analyzed the online database of the Spanish Network of Infection in Transplantation (RESITRA) found that Mycobacterium tuberculosis (M. tuberculosis) was responsible for almost a quarter of the cases of OI diagnosed after the sixth month posttransplantation. Cases of disseminated TB were not infrequent.
In this review, we focus on the importance of TB after liver transplantation (LT). We also discuss the most important strategies for the prevention of M. tuberculosis reactivation in LT recipients, particularly the role that fluoroquinolones (FQs) could play in the treatment of latent tuberculosis infection (LTBI) in LT candidates and recipients.
THE BURDEN OF M. TUBERCULOSIS AFTER LT
Active TB poses important challenges to clinicians who attend SOT recipients, with an incidence that can vary significantly-from 0.35% to 15%-depending on the prevalence of TB in a specific region or country and the type of SOT performed. A prospective study that included 16 transplant centers of the Spanish Network for Research in Infectious Diseases (REIPI) reported that LT recipients were at particular risk and had the third highest incidence rate, with 541 cases per 100000 transplant recipients per year, much higher than the rates in recipients of similar SOTs, such as kidney transplant (KT) and heart transplant (HT) recipients, which were 358 and 255/100000 patients per year, respectively.
Pulmonary TB (PTB) is the most frequently presenting type of M. tuberculosis infection after LT[8,9]. The risk for extrapulmonary (EPTB) or disseminated TB (DTB) is also higher than that observed in the general population; these conditions have an incidence rate of up to 33% among all patients[10,11]. In these cases, patients tend to complain only of fever or unspecific constitutional symptoms, without any other accompanying signs[6,12]; thus, clinicians should always consider this disease and have a high index of suspicion for active TB. Active TB treatment after LT is also problematic. The incidence of isoniazid-induced hepatotoxicity after LT is increased when isoniazid is combined with rifampicin, and accordant histological changes can be found in up to 83% of treated LT recipients. Interactions with immuno-suppressive drugs can also favor allograft rejection; rifampicin, a potent inducer of the cytochrome P450 enzyme system, can reduce the blood levels of most immuno-suppressants used in daily practice[15,16].
A number of studies have exhaustively addressed active TB in the LT setting. Abad et al, who reviewed 187 MEDLINE, EMBASE, and OVID publications, thoroughly described a total of 2082 cases of TB in SOT recipients, including 253 cases after LT. In this specific population, the relative frequency and median interval from trans-plantation to presentation of PTB, EPTB and DTB were 36.51%, 36.51% and 26.91% and 4, 9, and 48 mo, respectively. The liver allograft was involved in 30.0% of recipients in whom M. tuberculosis was isolated outside the pulmonary system, and 3.51% experienced allograft dysfunction or loss. Notably, 27.5% of LT recipients developed anti-TB drug-induced hepatoxicity, which was a higher percentage than in the overall cohort (19.56%). A systematic review and meta-analysis of TB after LT identified 139 cases of active TB. Most patients were diagnosed with EPTB (67%), and in 26, there was allograft involvement. TB drug therapy was stopped or changed in 35% of the patients, mostly due to hepatoxicity (80%). Póvoas et al described 8 cases of active TB after LT diagnosed in a transplant unit located in Lisbon, Portugal, over a five-year span. The incidence rates of PTB, EPTB and DTB were 37.5%, 37.5% and 25.0%, respectively. Liver allograft involvement was identified in 1 patient. Most cases were diagnosed more than 12 mo after transplantation. All patients received a four-drug treatment regimen, and one patient developed mild to moderate cholestasis that did not require therapy discontinuation.
The mortality rate of TB after LT can be as high as 50%, 20.31%, and 37.5%, respectively of the published studies[9,17,19].
TB can be secondary to reactivation of a latent infection or due to a new infection after transplantation, which can be acquired in the community or the healthcare environment or can be donor-derived[12,17]. However, the most common way of developing active TB disease after LT is by reactivation of a latent infection upon the initiation of immunosuppressive therapy. For this reason, in recent years, an important effort has been made to diagnose and treat LTBI in all SOT candidates, including LT candidates.
TREATMENT OF LTBI IN LT
LTBI can be defined as an infection by viable M. tuberculosis microorganisms that are resting in a dormant state. The LT candidate or recipient must have no signs, symptoms or radiographic findings of active TB disease.
Although a discussion concerning the controversies about the best method of diagnosing LTBI is beyond the scope of this article, all LT candidates should be screened for LTBI (Table 1). Screening requires collection of an exhaustive clinical history, a careful physical examination, a tuberculin skin test (TST) and/or tuberculosis interferon-γ release assay (IGRA), and a chest radiograph. Isoniazid (2.5 to 5 mg/kg per day, without exceeding 300 mg/day) plus vitamin B6 (25 to 50 mg/day) for 9 mo is the traditional treatment of choice for LTBI in the SOT population[20,22,23] (Table 1). Treatment should ideally be started before LT, although in candidates with advanced end-stage liver disease, current clinical guidelines recommend different LTBI treatments until liver function is stable after LT[22,23]. Another alternative to isoniazid is rifampicin for 4 months, although such a regimen should be restricted to the pretransplant period due to the risk of drug interactions with immunosuppressive agents. Combination treatment with isoniazid/rifampicin for 3 to 4 months carries an important cumulative risk of fulminant hepatitis and should not be prescribed to patients with liver disease. Two recent studies describing the experience with a 12-wk course of once-weekly directly observed therapy (DOT) with isoniazid plus rifapentine included 8 and 7 LT candidates[24,25] and reported adequate tolerance and a relatively high completion rate. However, data are still scarce, and future multicenter prospective studies are warranted to confirm the safety of this treatment regimen and to identify the most suitable LT candidates.
Table 1 Risk factors and indications of latent tuberculosis infection treatment in the liver transplant setting (adapted from Meije et al and Bosh et al).
Risk factors include:
Residence in a high-endemicity area
Age greater than 50 years
Homelessness or incarceration
Personal or donor history of TB
Diabetes mellitus, malnutrition, HIV infection, end-stage liver disease
Chest radiography or CT scan showing abnormalities
Intensification of immunosuppression for rejection; use of everolimus, sirolimus and T-cell-depleting antibodies
LTBI treatment should be prescribed to candidates with compensated cirrhosis or to recipients with normal liver allograft function and at least one of the following criteria:
TST (initial or after a booster effect) with an induration of ≥ 5 mm1
Personal or donor history of untreated or incorrectly treated TB
History of contact with a smear-positive TB patient
Residual TB lesions in an untreated patient
1Only if the candidate or the recipient has not been previously treated for latent tuberculosis infection or active tuberculosis. CT: Computed tomography; HIV: Human immunodeficiency virus; IGRA: Interferon-γ release assay; LTBI: Latent tuberculosis infection; TB: Tuberculosis; TST: Tuberculin skin test.
Thus, LTBI treatment in LT candidates or recipients is especially difficult. Isoniazid is usually poorly tolerated, and it has been suggested that drug-induced hepatitis can occur in up to 6%-20% of LT recipients. In the RESITRA study, only 29.6% of LT patients with a TST positivity actually received treatment, a rate substantially lower than that observed in the overall cohort of SOT recipients (mean of 43.5%). A recent European survey performed in 55 transplant programs from 19 countries reported that the rate of LTBI treatment prescription was significantly lower for LT candidates than for other SOT candidates (38% vs 73%, respectively). A retrospective Canadian study that compared the tolerability of LTBI treatment in 23 LT candidates and 24 LT recipients against 130 non-liver SOT candidates plus 23 non-LT SOT recipients concluded that the completion rate of LTBI therapy with isoniazid and/or rifampicin was significantly lower in LT candidates or recipients than in non-LT candidates and recipients [36.1% vs 73.9%, respectively; odds ratio (OR) = 0.20; P < 0.001]. Therapy discontinuation due to liver enzyme elevation was also more frequent in LT candidates and recipients than in non-LT candidates and recipients (28.3% vs 3.5%; OR = 10.48; P value < 0.001). A study that included 15 LT recipients diagnosed with LTBI and treated with 300 mg of daily isoniazid plus 50 mg of pyridoxine for six months reported that 53% of patients required premature discontinuation of the therapy. The most important side effects were thrombocytopenia, hepatotoxicity, rejection, and tacrolimus toxicity. All patients had started LTBI treatment within the first six months after transplantation. A similar South Korean study reported that the incidence rate of isoniazid-induced hepatotoxicity was significantly lower in LT recipients with an aspartate aminotransferase (AST) level lower than 50 than in those with an AST level higher than 50. The authors of both studies suggested deferring LTBI treatment until liver allograft function was stable, avoiding its prescription in the early post-LT period[29,30]. However, this delay could lead to an increased risk of TB reactivation, as most cases of active TB are diagnosed within the first months after transplantation[6,8,12]. Moreover, in candidates already receiving isoniazid-based LTBI treatment regimen, therapy must be stopped at the time of LT and resumed only when the allograft is stabilized, delaying the end of treatment.
EXPERIENCE WITH FQs FOR THE TREATMENT OF LTBI IN LT
Most data for LTBI treated with FQ-based regimens are derived from preventive therapy of multidrug resistant TB cases. Levofloxacin and moxifloxacin have been shown to exhibit good in vitro activity against TB[31,32]. In addition, in these series, levofloxacin and moxifloxacin appeared to be well tolerated and cost-effective[33,34], with treatment completion rates as high as 83% and 100%. FQs, such as levofloxacin, also have a lower hepatotoxic potential than other anti-TB drugs. However, it must be remembered that serious side effects are associated with FQs, such as QT interval prolongation, tenosynovitis and an increased risk of aortic aneurysm and dissection, which is a theoretical concern in long-term therapeutic regimens. Data regarding the risk of rhegmatogenous retinal detachment are still under debate due to contradictions in the published data[40,41]. Furthermore, the European Medicines Agency (EMA) recently issued a warning regarding the risk of hepatotoxicity associated with moxifloxacin, recommending close follow-up during treatment.
In the LT setting, FQs have been used particularly as part of isoniazid- or rifampin-sparing regimens prescribed to recipients diagnosed with active TB. Lee et al described nine LT recipients diagnosed with active TB and treated with a therapeutic regimen that principally included ethambutol, cycloserine and a FQ (levofloxacin in 6, moxifloxacin in 1 and ofloxacin in 2 recipients). All nine patients successfully completed treatment and did not experience any apparent FQ-associated side effects. Several case reports of LT recipients treated with a therapeutic regimen that included levofloxacin[43,44] or moxifloxacin have also been published. FQs were administered for periods ranging from 2 mo to 18 mo. No cases of FQ-induced adverse effects were reported.
Regrettably, data concerning the use of FQs in LT for LTBI treatment are still scarce and mostly based on retrospective single-center studies with a small series of patients (Table 2). To date, only one prospective multicenter randomized study has compared the efﬁcacy and safety of levoﬂoxacin (500 mg daily for 9 mo) initiated before transplantation to isoniazid (300 mg every day for 9 mo) initiated between 3 and 6 months after transplantation. Isoniazid was started only when liver function was considered stable, i.e., when the transaminase, alkaline phosphatase, and bilirubin levels did not exceed twice the upper limit of normal. The primary efﬁcacy endpoint was the number of patients who developed tuberculosis at 18 mo after tr-ansplantation, whereas the secondary aim was to determine whether adverse events limited the efﬁcacy of levoﬂoxacin. The study was active between January 2012 and February 2014, when a safety analysis resulted in suspension of the trial. Notably, 6 of the 33 candidates (18.2%) in the levofloxacin arm developed tenosynovitis, which required stopping the drug, and 6.1% were diagnosed with severe hepatotoxicity, which resolved after discontinuing the antibiotic. Tenosynovitis occurred from 14 to 133 days after the start of prophylaxis. The authors concluded that levofloxacin was associated with an unacceptably high incidence of tenosynovitis in LT candidates. However, it should be mentioned that only 18 of the 31 LT recipients in the isoniazid arm (58.1%) actually began prophylaxis, and only 10 (32.2%) completed the 9-month treatment course. Hepatotoxicity, which was observed in 38.9% of patients receiving isoniazid, was the most common adverse event associated with this drug. No cases of TB were diagnosed during follow-up.
Table 2 Reported fluoroquinolone-induced adverse events and outcomes associated with treatment of latent mycobacterium tuberculosis infection in liver transplantation.
1Fluoroquinolone treatment was primarily stopped due to tenosynovitis (5 patients [45.4%]) and hepatotoxicity [2 patients (18.2%)].
2Treatment was withdrawn due to tenosynovitis [1 patient (50.0%)] and severe constitutional symptoms [1 patient (50.0%)].
3Data not available on the other 6 patients.
4Prophylaxis was stopped due to tenosynovitis [2 patients (50.0%)], hepatotoxicity [one patient (25.0%)], and transient optical neuritis [one recipient (25.0%)]. FQ: Fluoroquinolone; KT: Kidney transplant; LT: Liver transplant; NA: Data not available.
Since the publication of the RESITRA cohort study, several small single-center reports have been published (Table 2). Tien et al described an experience with 44 LT candidates treated for LTBI, including 25 patients who received FQ (17, levoﬂoxacin; and 8, moxiﬂoxacin). Adverse events were described in 14 of the 25 (56%) treated patients, including 4 (16%) with musculoskeletal symptoms that ranged from diffuse joint pain to unilateral tendinopathy. One patient required permanent FQ discontinuation, whereas the remaining 3 patients were able to complete the 9-mo treatment after temporary suspension of the drug. The incidence of adverse events leading to permanent discontinuation significantly differed among the drugs, From 8% for FQ to 33% and 40% for rifampicin and isoniazid, respectively. The same authors also described 6 LT recipients who received FQs after transplantation for LTBI. Although one recipient presented joint pain, he was able to complete treatment. No cases of FQ-induced hepatotoxicity prior to or after transplantation were reported, and none of these patients developed TB during follow-up. Grim et al published a retrospective study that focused on the tolerability and completion of LTBI treatment in SOT candidates. Of the 129 patients included, 30 were LT and 8 were LT/kidney transplant candidates, and 8 (21.0%) received moxifloxacin. Although much data are lacking, in this particular group, there were no early discontinuations of the drug, and at least 2 patients (25.0%) completed treatment (data for the other 6 candidates concerning the end of treatment was not retrieved). Sgarabotto et al reported an experience with 35 LT recipients who received a combination course of levofloxacin and ethambutol from posttransplant day 1 until hospital discharge and three times weekly for 1 year thereafter. Four patients (11.4%) developed side events that required treatment cessation. Interestingly, during follow-up, TB was diagnosed in 2 patients (5.7%); one had discontinued LTBI treatment due to drug-induced side effects. Anecdotally, a combination of levofloxacin and pyrazinamide for MDR TB prophylaxis prescribed to 57 SOT recipients, including 3 LT patients, resulted in a high incidence of side effects (approximately 1.4 events/patient) with very limited tolerability.
Active TB is a serious OI after SOT, particularly after LT. Treatment is difficult due to the increased risk of drug-induced liver allograft injury, fulminant hepatic failure and rejection. Most centers either do not prescribe or delay the start of LTBI treatment, as it seems reasonable to consider therapy with isoniazid only in patients with compensated cirrhosis or good liver allograft function and in whom hepatotoxicity can be closely monitored. FQs, which have good anti-TB activity and appear to be less hepatotoxic than isoniazid, could be an alternative for LTBI treatment in the LT setting. Data in some points are small and conflicting, with the rate of permanent withdrawal of the FQ due to side effects ranging from 6% to 33% of all treated patients. More studies are necessary to determine which patients could have the greatest benefit from this therapeutic regimen as well as to compare the tolerability and side effects of levofloxacin vs moxifloxacin and the risk of multidrug-resistant gram-negative bacterial selection. These studies would also allow us to determine the real efficacy of FQs in preventing LTBI in the LT setting.
Manuscript source: Invited manuscript
Specialty type: Gastroenterology and hepatology
Country of origin: Spain
Peer-review report classification
Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Tchilikidi KY S-Editor: Ma RY L-Editor: A E-Editor: Zhang YL
Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, Cervera C, Len O, Carratala J, Cisneros JM, Bou G, Muñoz P, Ramos A, Gurgui M, Borrell N, Fortún J, Moreno A, Gavalda J; Spanish Network for Research in Infectious Diseases. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort.Clin Infect Dis. 2009;48:1657-1665.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 167][Cited by in F6Publishing: 130][Article Influence: 13.9][Reference Citation Analysis (0)]
Aguado JM, Herrero JA, Gavaldá J, Torre-Cisneros J, Blanes M, Rufí G, Moreno A, Gurguí M, Hayek M, Lumbreras C, Cantarell C. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA.Transplantation. 1997;63:1278-1286.
[PubMed] [DOI][Cited in This Article: ]
Schluger LK, Sheiner PA, Jonas M, Guarrera JV, Fiel IM, Meyers B, Berk PD. Isoniazid hepatotoxicity after orthotopic liver transplantation.Mt Sinai J Med. 1996;63:364-369.
[PubMed] [DOI][Cited in This Article: ]
Meyers BR, Papanicolaou GA, Sheiner P, Emre S, Miller C. Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens.Transplantation. 2000;69:64-69.
[PubMed] [DOI][Cited in This Article: ]
Póvoas D, Machado J, Perdigoto R, Morbey A, Veloso J, Glória H, Mateus É, Martins A, Maltez F, Barroso E. Tuberculosis in Liver Transplant Recipients: A Report of Eight Cases During a Five Year Period.Acta Med Port. 2017;30:41-46.
[PubMed] [DOI][Cited in This Article: ]
Lee YT, Hwang S, Lee SG, Kim KW, Choi NK, Park GC, Yu YD, Yoo JW, Kim WS, Shim TS. Living-donor liver transplantation in patients with concurrent active tuberculosis at transplantation.Int J Tuberc Lung Dis. 2010;14:1039-1044.
[PubMed] [DOI][Cited in This Article: ]
Torre-Cisneros J, San-Juan R, Rosso-Fernández CM, Silva JT, Muñoz-Sanz A, Muñoz P, Miguez E, Martín-Dávila P, López-Ruz MA, Vidal E, Cordero E, Montejo M, Blanes M, Fariñas MC, Herrero JI, Rodrigo J, Aguado JM. Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial.Clin Infect Dis. 2015;60:1642-1649.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 39][Cited by in F6Publishing: 32][Article Influence: 6.5][Reference Citation Analysis (0)]
Lou HX, Shullo MA, McKaveney TP. Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population.Pharmacotherapy. 2002;22:701-704.
[PubMed] [DOI][Cited in This Article: ]